Allegion exhibits steady fundamental growth with revenue rising from $3.77B in 2024 to $4.07B in 2025 and EPS expanding to $7.44, yet the stock trades at a significant discount to its 200-day moving average ($131.60 vs. $159.85) following a Q1 2026 earnings miss. The valuation appears reasonable at a 17.7x P/E, roughly in line with peers, but the technical breakdown and recent margin pressure from rising costs warrant caution. Insider activity is mixed, with a director purchase in March 2026 offset by consistent officer selling, suggesting no clear signal from management. Hold until the stock stabilizes technically or fundamentals re-accelerate to confirm the growth trajectory.
Non-Residential Construction Slowdown
Allegion's Americas non-residential business is a key growth driver; a downturn in commercial construction spending could reverse recent revenue gains.
Margin Compression
Q1 2026 earnings missed estimates due to rising costs and margin pressure; persistent input cost inflation could erode profitability despite revenue growth.
Technical Weakness
The stock is trading below both its 50-day ($139.35) and 200-day ($159.85) moving averages with an RSI of 44, indicating sustained selling pressure that could attract further momentum-based selling.
Insider Selling Pattern
Multiple officers, including the CEO and SVP of Innovation, disposed of shares in early 2026, which may signal caution about near-term valuation or prospects.